AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

172.310

+0.7400.43%

Volume:1.50M

Turnover:259.17M

Market Cap:82.52B

PE:-23.03

High:175.365

Open:172.800

Low:171.000

Close:171.570

52wk High:219.589

52wk Low:90.000

Shares:478.91M

Float Shares:478.91M

Volume Ratio:1.27

T/O Rate:0.31%

Dividend:4.12

Dividend Rate:2.39%

EPS(TTM):-7.481

EPS(LYR):-7.481

ROE:-15.83%

ROA:7.26%

PB:3.99

PE(LYR):-23.03

Loading ...

Overview Company News Filings

Dividend Powerhouses 3%+ Yield Three Stocks Hiding Income Upside

Simply Wall St.

FACTBOX-Global drugmakers invest billions to boost US presence

Why CSL (ASX:CSL) Is Up 9.8% After Cutting FY26 Guidance On Impairments And Channel Shifts

Simply Wall St.

What did Morningstar subscribers buy and sell during May?

Morning Star AU

Chart of the Week: Is CSL finally turning the ship around?

Morning Star AU

CSL Unit Signs Five-Year Lease Contract with Clever Culture Systems for APAS Independence Instrument

MT Newswires Live

CSL Bulls Say Margin Forecasts Are Overly Optimistic -- Market Talk

A Look At CSL (ASX:CSL) Valuation After Guidance Cut Impairments CEO Change And Share Price Rebound

Simply Wall St.

How Investors Are Reacting To CSL (ASX:CSL) US$5b Vifor Impairment And Guidance Reset

Simply Wall St.

Stock Track | CSL Soars 5.02% Intraday on UK Regulatory Approval for AUJEMFLU Vaccine

UK'S MHRA Grants Marketing Authorisation For AUJEMFLU To Protect Adults Over 50 Against Flu

UK's Mhra: Granted Marketing Authorisation for Adjuvanted Trivalent Influenza Vaccine (Aujemflu) to Protect Adults Aged 50 & Over Against Flu

THOMSON REUTERS

BUZZ-Morningstar maintains fair value for CSL despite underperformance

ASX Midday Sector Update: Information Technology Stocks Jump, Healthcare Sector Falls

MT Newswires Live

BUZZ-Australia's CSL falls on Jefferies downgrade to "hold"

ASX Biggest Losers

MT Newswires Live

CSL's Ex-Bull Worries About Intensifying Competition to Vifor -- Market Talk

CSL Says CEO Indirectly Acquires Nearly AU$108,000 Worth of Shares

MT Newswires Live

CSL's Seqirus to discontinue bacterial infection drug amid generic competition

Australia says CSL unit Seqirus to discontinue Benpen injections from November

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/CSL.AU/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":172.31,"timestamp":1788243120000,"preClose":171.57,"halted":0,"volume":1501636,"delay":0,"changeRate":0.004313108352276092,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.48074930540893,"marketStatus":"Closed","change":0.74,"latestTime":"09-01 16:12:00 AEST","open":172.8,"high":175.365,"low":171,"amount":259171238,"amplitude":0.025442,"askPrice":172.31,"askSize":5,"bidPrice":172.2,"bidSize":250,"shortable":3,"etf":0,"ttmEps":-7.48074930540893,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":171.57,"dividendRate":0.023897,"openAndCloseTimeList":[[1788220800000,1788242400000]],"volumeRatio":1.265648,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":171.57,"auctionPrice":172.33,"auctionVolume":317793,"auctionTime":1788243005735,"referencePrice":172.31,"referenceTime":1788258603092,"auction":3,"marketStatus":"盘后竞价","timestamp":1788243005735}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.480749,"volumeRatio":1.265648,"shares":478911979,"dividePrice":4.1177,"high":175.365,"amplitude":0.025442,"preClose":171.57,"low":171,"week52Low":90,"pbRate":"3.99","psRate":"3.74","week52High":219.589,"institutionHeld":0,"latestPrice":172.31,"committee":0.960784,"eps":-7.48074930540893,"divideRate":0.023897,"volume":1501636,"delay":0,"ttmEps":-7.48074930540893,"open":172.8,"prevYearClose":170.408,"prevWeekClose":172.32,"prevMonthClose":171.57,"prevQuarterClose":114.74,"fiveDayClose":173.64,"twentyDayClose":128.83,"sixtyDayClose":99.47,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.018567360626050477},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2644764240","title":"Dividend Powerhouses 3%+ Yield Three Stocks Hiding Income Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2644764240","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644764240?lang=en_us&edition=fundamental","pubTime":"2026-06-17 00:22","pubTimestamp":1781626934,"startTime":"0","endTime":"0","summary":"With inflation trends diverging across regions and central banks keeping investors on edge, many are looking for ways to put cash to work without relying solely on share price moves. That is where Dividend Powerhouses with 3%+ yields come in, focusing on companies that are paying more than a 5% dividend yield that is covered, growing and relatively stable. In this article, the spotlight is on income resilience in a world of shifting rates and mixed growth signals, and it will reveal 3 of the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/dividend-powerhouses-3-yield-three-stocks-hiding-income-upsi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/dividend-powerhouses-3-yield-three-stocks-hiding-income-upsi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GDX","IAUM","XME","BEGS","RING","BAR","DULL","DUST","IAUI","UYM","IAU","JDST","GDXD","GLTR","OUNZ","PHYS","CHAT","DBC","GOAU","GDXJ","CBA.AU","BTGD","GLDM","VIG","AGIX","AAAU","GDXU","ARTY","EVN.AU","GLL","AIPO","JNUG","SHNY","XAO.AU","UGL","USG","DGP","SGDM","GDXY","CSL.AU","PICK","CEF","DZZ","FGDL","SGOL","XKO.AU","AI","XJO.AU","GBUG","GOLY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643770522","title":"FACTBOX-Global drugmakers invest billions to boost US presence","url":"https://stock-news.laohu8.com/highlight/detail?id=2643770522","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643770522?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:55","pubTimestamp":1781520920,"startTime":"0","endTime":"0","summary":"FACTBOX-Global drugmakers invest billions to boost US presence Recasts paragraph 1, 2; updates headline","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nL4N42N0V9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","LU0098860793.USD","LU1046234339.USD","IE00BGHQF631.EUR","03165","AMGN","IE00B19Z3B42.SGD","LU0070302665.USD","LU0985481810.HKD","CSL.AU","LU2023250504.SGD","LU2237443549.SGD","LU2242646821.SGD","LU1929549753.HKD","SG9999018865.SGD","LLYX","ELIL","MRK","LU1430594728.SGD","LU1699723380.USD","LU0047473722.EUR","LU0211327993.USD","PFE","IE00BLSP4452.SGD","AZN.UK","IE00BZ1G4Q59.USD","LU0211331839.USD","LU0109391861.USD","LU0976567544.SGD","GILD","IE00BJT1NW94.SGD","BK4592","LU0708994859.HKD","IE00BSNM7G36.USD","ABBV","LLY","LU0661504455.SGD","ELIS","LLYZ","LU0158827948.USD","LU1496350502.SGD","JNJ","SG9999001440.SGD","LU0029864427.USD","LU2237438978.USD","BIIB","LLII","LU1934455194.USD","SG9999003800.SGD","LU0942090050.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643214189","title":"Why CSL (ASX:CSL) Is Up 9.8% After Cutting FY26 Guidance On Impairments And Channel Shifts","url":"https://stock-news.laohu8.com/highlight/detail?id=2643214189","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643214189?lang=en_us&edition=fundamental","pubTime":"2026-06-13 16:26","pubTimestamp":1781339195,"startTime":"0","endTime":"0","summary":"CSL has recently cut its FY26 revenue and profit forecasts following earnings downgrades, writedowns and impairments tied to shifts in US immunoglobulin sales channels and softer China albumin prices, ahead of its full-year results and dividend announcement previously scheduled for 18 August 2026.\nDespite these setbacks, investors appear increasingly focused on CSL’s turnaround prospects and the possibility that future impairments could be more contained than previously feared.\nWe’ll now...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/why-csl-asxcsl-is-up-98-after-cutting-fy26-guidance-on-impai","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/why-csl-asxcsl-is-up-98-after-cutting-fy26-guidance-on-impai","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4086","BK7511","CSL.AU","BK7067","LU0728928796.USD","AIPO","CSL","BK7501","BK7508","LU1169589451.USD","SGXZ23171101.USD","LU1169590202.USD","SG9999004303.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642731405","title":"What did Morningstar subscribers buy and sell during May?","url":"https://stock-news.laohu8.com/highlight/detail?id=2642731405","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642731405?lang=en_us&edition=fundamental","pubTime":"2026-06-11 00:00","pubTimestamp":1781107200,"startTime":"0","endTime":"0","summary":"Sharesight is a portfolio tracker that is integrated into Morningstar Investor. Their data shows the top 20 trades by Morningstar subscribers in May. Sharesight’s data above ranks total trading activi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/what-did-morningstar-subscribers-buy-sell-during-may","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/what-did-morningstar-subscribers-buy-sell-during-may","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["CSL.AU","QRE.AU","BK4588","QFN.AU","IISV.AU","XKO.AU","BBOZ.AU","IMLC.AU","VAP.AU","VAS.AU","BK4550","XJO.AU","GEAR.AU","XLV","BK4112","IIGF.AU","MORN","OZR.AU","BK7501","ZYAU.AU","DACE.AU","GIVE.AU","XAO.AU","IOZ.AU","LABU","BK7067","SEMI.AU","BK4598","SLF.AU","XBI","BK4585","BK7508","SHL.AU","BK7511","BK4581","LU1878469433.USD","LU2065731478.USD","BEAR.AU","STW.AU","EIGA.AU","E200.AU","BK7124","FDN","OZF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642405202","title":"Chart of the Week: Is CSL finally turning the ship around?","url":"https://stock-news.laohu8.com/highlight/detail?id=2642405202","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642405202?lang=en_us&edition=fundamental","pubTime":"2026-06-11 00:00","pubTimestamp":1781107200,"startTime":"0","endTime":"0","summary":"The week’s insights come from equity strategist Lochlan Halloway’s latest analysis of CSL Ltd (ASX.CSL).CSL faces headwinds but shares remain cheap ahead of expected margin recoveryCSL is a global lea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/chart-week-is-csl-finally-turning-ship-around","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/chart-week-is-csl-finally-turning-ship-around","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["BK7508","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LU1988902786.USD","LU1169590202.USD","LU2264538146.SGD","LU2211815571.USD","CSL","LU1064131342.USD","IE00BFMHRM44.USD","BK7501","LU0823414478.USD","IE0031619046.USD","GTLS","LU2048586759.USD","BK4161","LU2249611893.SGD","CSL.AU","LU0728928796.USD","SGXZ23171101.USD","BK7511","BK4086","LU2355687059.USD","IE00B19Z4B17.USD","LU1169589451.USD","SG9999004303.SGD","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642845800","title":"CSL Unit Signs Five-Year Lease Contract with Clever Culture Systems for APAS Independence Instrument","url":"https://stock-news.laohu8.com/highlight/detail?id=2642845800","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642845800?lang=en_us&edition=fundamental","pubTime":"2026-06-09 09:12","pubTimestamp":1780967525,"startTime":"0","endTime":"0","summary":"CSL's  CSL Behring subsidiary signed a five-year contract with Clever Culture Systems  for the lease of an APAS Independence instrument and environmental monitoring analysis modules, according to a Tuesday filing with the Australian bourse.APAS Independence is an instrument that automates the imaging, interpretation, and reporting of microbial growth on culture plate media for labs.The contract will be paid in monthly installments, with an initial minimum non-cancellable period of six months following the start of the company's formal validation, which must occur on or before Dec. 31, the filing said.CSL shares rose 1% in morning trade on Tuesday, while Clever Culture Systems shares were up 5%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LU0728928796.USD","LU1169590202.USD","BK7511","BK7501","SGXZ23171101.USD","LU1169589451.USD","BK7007","SG9999004303.SGD","BK4086","CSL.AU","BK7508","CSL","CC5.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642745862","title":"CSL Bulls Say Margin Forecasts Are Overly Optimistic -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2642745862","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642745862?lang=en_us&edition=fundamental","pubTime":"2026-06-09 08:43","pubTimestamp":1780965780,"startTime":"0","endTime":"0","summary":"0043 GMT - CSL's bulls at UBS think analysts elsewhere are too optimistic about the scale of margin improvement the Australian biotech can deliver in its next fiscal year. UBS analysts keep a buy rating on the stock but warn clients in a note that the consensus forecast of a 90-basis-point margin expansion at CSL's plasma-product business is too high. They expect to see an improvement on a 10% lift in collections per donor, which they say will help offset price and competitive pressures. However, there will be no return to pre-Covid levels, they add. The UBS analysts are untroubled by the hefty impairments CSL has announced. UBS cuts its target price 9.7% to A$158.00. Shares are up 0.6% at A$98.49. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK4534","LU1829250122.USD","SGXZ23171101.USD","BK4588","SG9999004303.SGD","IE0034235071.USD","LU3187612489.SGD","LU1169589451.USD","BK4585","BK7067","LU1863844749.USD","LU1169590202.USD","BK4086","CSL","BK7501","BK7508","CSL.AU","LU1863844665.USD","UBS","BK4118","LU0728928796.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641239101","title":"A Look At CSL (ASX:CSL) Valuation After Guidance Cut Impairments CEO Change And Share Price Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2641239101","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641239101?lang=en_us&edition=fundamental","pubTime":"2026-06-08 12:34","pubTimestamp":1780893256,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) is back in focus after cutting its FY26 revenue guidance, flagging about US$5b in additional Vifor related impairments and progressing a CEO transition along with broader commercial restructuring.\nSee our latest analysis for CSL.\nCSL’s share price rose 5.75% in the last session to A$97.91 and is up 1.35% over seven days. However, the 30 day share price return is down 18.33% and the one year total shareholder return is down 58.53%, which points to fading longer term momentum...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/a-look-at-csl-asxcsl-valuation-after-guidance-cut-impairment","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/a-look-at-csl-asxcsl-valuation-after-guidance-cut-impairment","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL.AU","BK7501","SGXZ23171101.USD","SG9999004303.SGD","CSL","BK7511","LU0728928796.USD","LU1169589451.USD","BK7067","BK7508","LU1169590202.USD","BK4086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641123670","title":"How Investors Are Reacting To CSL (ASX:CSL) US$5b Vifor Impairment And Guidance Reset","url":"https://stock-news.laohu8.com/highlight/detail?id=2641123670","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641123670?lang=en_us&edition=fundamental","pubTime":"2026-06-06 03:22","pubTimestamp":1780687323,"startTime":"0","endTime":"0","summary":"In recent weeks, CSL Limited cut its FY26 revenue and earnings guidance, flagged around US$5.00 billion in additional non-cash impairments largely tied to CSL Vifor, and continued a leadership transition while pursuing a broad operational transformation program.\nThese developments highlight how earlier capital allocation decisions and current restructuring efforts are reshaping CSL’s risk profile, management credibility, and future profitability mix across its core plasma, vaccines, and iron...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-are-reacting-to-csl-asxcsl-us5b-vifor-impairme","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-are-reacting-to-csl-asxcsl-us5b-vifor-impairme","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","SGXZ23171101.USD","BK4023","BK4211","AIYY","CHAT","CSL.AU","ISBC","CSL","LU0728928796.USD","BK7067","ARTY","BK7511","SG9999004303.SGD","BK4528","BK7508","BK7501","LU1169589451.USD","AGIX","LU1169590202.USD","AI","BK4585","BK4587","BK4543","BK4086","BK4551","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144650764","title":"Stock Track | CSL Soars 5.02% Intraday on UK Regulatory Approval for AUJEMFLU Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1144650764","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144650764?lang=en_us&edition=fundamental","pubTime":"2026-06-05 11:36","pubTimestamp":1780630616,"startTime":"0","endTime":"0","summary":"CSL LIMITED's stock soared 5.02% during intraday trading on Friday, following positive regulatory news from the United Kingdom.The UK's Medicines and Healthcare products Regulatory Agency (MHRA)...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CSL.AU"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2641716931","title":"UK'S MHRA Grants Marketing Authorisation For AUJEMFLU To Protect Adults Over 50 Against Flu","url":"https://stock-news.laohu8.com/highlight/detail?id=2641716931","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641716931?lang=en_us&edition=fundamental","pubTime":"2026-06-05 00:26","pubTimestamp":1780590376,"startTime":"0","endTime":"0","summary":"June 4 (Reuters) - UK's MHRA::*UK'S MHRA: GRANTED MARKETING AUTHORISATION FOR ADJUVANTED TRIVALENT INFLUENZA VACCINE (AUJEMFLU) TO PROTECT ADULTS AGED 50  OVER AGAINST FLU*Further company coverage: CS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nRSDRbZ0f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7511","BK7501","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640165171","title":"UK's Mhra: Granted Marketing Authorisation for Adjuvanted Trivalent Influenza Vaccine (Aujemflu) to Protect Adults Aged 50 & Over Against Flu","url":"https://stock-news.laohu8.com/highlight/detail?id=2640165171","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640165171?lang=en_us&edition=fundamental","pubTime":"2026-06-04 23:03","pubTimestamp":1780585404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C02H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","CSL.AU","BK7511","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640260959","title":"BUZZ-Morningstar maintains fair value for CSL despite underperformance","url":"https://stock-news.laohu8.com/highlight/detail?id=2640260959","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640260959?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:33","pubTimestamp":1780436006,"startTime":"0","endTime":"0","summary":"BUZZ-Morningstar maintains fair value for CSL despite underperformance** Morningstar keeps A$165 fair value estimate despite headwinds faced by Australia's CSL Ltd CSL.AX ** Earlier this year, the biotechnology giant cut its annual profit citing regulatory headwinds and weak performance including other reasons** The Investment research firm says shares are undervalued, says it is more optimistic on co's stock than the market on plasma demand and margins ** Morningstar sees co's immunoglobulin revenue to grow at a 10-year compound annual growth rate  of 5% on higher volumes from population growth, rising diagnosis rates including others** Also forecasts plasma gross margins to lift to 100 basis points till FY35, cites efficiency initiatives and rationalization of high-cost collection centers** Says market for plasma products has become increasingly competitive and most cost savings will be offset by price competition ** Adds, separation of CSL Seqirus to  help CSL to refocus on the core","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nL6N42A17U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4598","CSL.AU","BK7067","BK4112","BK7508","LU2065731478.USD","MORN","BK7511","BK7501","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640663987","title":"ASX Midday Sector Update: Information Technology Stocks Jump, Healthcare Sector Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2640663987","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640663987?lang=en_us&edition=fundamental","pubTime":"2026-06-01 10:53","pubTimestamp":1780282407,"startTime":"0","endTime":"0","summary":"Information technology stocks advanced more than 5% at midday Monday.Xero (ASX:XRO) gained 8% in recent trade.On the flip side, the healthcare sector struggled, shedding nearly 2%.CSL (ASX:CSL) shares fell almost 2% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XRO.AU","XBI","BK7016","BK7501","BK7511","XLV","BK7067","BK4137","LABU","LU0128526141.USD","BK7508","LU0029874061.USD","III","BK4585","BK4588","CSL.AU","BK7503","BK4581","BK4134","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639649752","title":"BUZZ-Australia's CSL falls on Jefferies downgrade to \"hold\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2639649752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639649752?lang=en_us&edition=fundamental","pubTime":"2026-05-29 13:36","pubTimestamp":1780032982,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL falls on Jefferies downgrade to \"hold\"** Shares of biotechnology major CSL Ltd CSL.AX fall as much as 2.5% to A$95.16, their lowest level since May 12 ** Jefferies downgrades CSL to \"hold\" from \"buy\", citing limited near-term growth in its Vifor division amid rising competitive pressures** Cuts price target to A$108 from A$195 after shifting to peerbased valuation and lowering earnings forecasts** Says CSL Vifor faces pricing pressure from generic iron products and insurer step-edits favouring lower-cost treatments** Adds lower-than-expected CHF/USD forex forecast to impact Vifor revenue and profit** Stock down 43.7% YTD, including the day's moves  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nL4N4260GG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7067","CSL.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639643794","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2639643794","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639643794?lang=en_us&edition=fundamental","pubTime":"2026-05-29 10:57","pubTimestamp":1780023474,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest losses on Friday.Energy Resources of Australia : -20%, AU$0.002Champion Iron : -5%, AU$4.54Superloop : -5%, AU$3.42Weebit Nano : -4%, AU$7.05Helia Group : -3%, AU$4.84GemLife Communities Group : -3%, AU$4.45Karoon Energy : -3%, AU$1.94Viva Energy Group : -2%, AU$2.11Ryman Healthcare : -2%, AU$1.88CSL : -2%, AU$96.05","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7511","BK7129","BK7145","SLC.AU","BK7083","ERA.AU","VEA.AU","BK7123","BK7069","GLF.AU","BK7015","BK7065","BK7067","WBT.AU","BK7501","BK7113","BK7508","CSL.AU","CIA.AU","BK7098","HLI.AU","KAR.AU","RYM.AU","BK7160","BK7142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639439614","title":"CSL's Ex-Bull Worries About Intensifying Competition to Vifor -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2639439614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639439614?lang=en_us&edition=fundamental","pubTime":"2026-05-29 07:01","pubTimestamp":1780009260,"startTime":"0","endTime":"0","summary":"CSL loses a bull in Jefferies, which thinks growth in the pharmaceutical company's Vifor business appears difficult in the short term. CSL is competing with rival drugs on price, particularly from generic medication Venofer. It's also facing negative currency swings. \"We continue to expect impacts from generics in the near-term, and so continue to forecast a 15% decline in FY27 Vifor iron revenue, with a resultant 300 basis-points decline in CSL Vifor Ebit margin,\" analyst David Stanton says. Jefferies downgrades CSL to hold, from buy. Vifor's challenges add to headwinds buffeting CSL'S Behring division, which accounts for most of its revenue. Jefferies's price target falls 45% to A$108.00/share. CSL ended Thursday at A$97.59. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","CSL.AU","BK7508","SG9999004303.SGD","LU1169589451.USD","LU0728928796.USD","LU1169590202.USD","SGXZ23171101.USD","BK7511","BK7067","BK4086","CSL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638777655","title":"CSL Says CEO Indirectly Acquires Nearly AU$108,000 Worth of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2638777655","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638777655?lang=en_us&edition=fundamental","pubTime":"2026-05-28 10:31","pubTimestamp":1779935491,"startTime":"0","endTime":"0","summary":"CSL  said Chief Executive Gordon Naylor indirectly acquired 1,100 CSL ordinary shares in an on-market purchase on Wednesday for a consideration of AU$107,800, according to a Thursday Australian bourse filing.Naylor-Stewart Investments, as trustee for the Naylor-Stewart Family Trust, holds the shares.CLS's shares fell almost 2% in recent trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","LU0728928796.USD","LU1169590202.USD","CSL","LU1169589451.USD","SGXZ23171101.USD","BK4086","BK7067","BK7511","CSL.AU","SG9999004303.SGD","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638570468","title":"CSL's Seqirus to discontinue bacterial infection drug amid generic competition","url":"https://stock-news.laohu8.com/highlight/detail?id=2638570468","media":"Reuters","labels":["productRelease","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638570468?lang=en_us&edition=fundamental","pubTime":"2026-05-27 15:26","pubTimestamp":1779866783,"startTime":"0","endTime":"0","summary":"UPDATE 2-CSL's Seqirus to discontinue bacterial infection drug amid generic competitionRecasts with company and TGA's commentsMay 27 (Reuters) - The vaccine arm of Australian biopharmaceutical giant C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nL4N4240K3:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CSL's Seqirus to discontinue bacterial infection drug amid generic competition","news_tag":"productRelease,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7501","BK7067","BK7508","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638957267","title":"Australia says CSL unit Seqirus to discontinue Benpen injections from November","url":"https://stock-news.laohu8.com/highlight/detail?id=2638957267","media":"Reuters","labels":["productRelease","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638957267?lang=en_us&edition=fundamental","pubTime":"2026-05-27 15:15","pubTimestamp":1779866136,"startTime":"0","endTime":"0","summary":"Australia says CSL unit Seqirus to discontinue Benpen injections from NovemberMay 27  - Australia's drug regulator said on Wednesday it was notified by biopharmaceutical giant CSL's CSL.AX unit Seqirus that it will be discontinuing all strengths of their Benpen injection products progressively due to commercial reasons. CSL's vaccine arm notified the regulator that the discontinuation will start with the 600 milligrams  strength from 30 November 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nL4N4240JS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7501","BK7511","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}